Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Epclusa and Vosevi in Chronic HCV
NCT04211909Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2020
- Primary completion
- Nov 2020
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label trial of velpatasvir and sofosbuvir + velpatasvir + voxilaprevir in hepatitis C (HCV) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response 12 Weeks After Discontinuation and Percentage of Participants Who Permanently Discontinued the Study Drug Due to an Adverse Event. Started Jan 2020; status: completed.
02
Drugs
velpatasvirsofosbuvir + velpatasvir + voxilaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04211909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04211909.